MedTrace Logo

Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor

NCT01883869 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-09-13

No results posted yet for this study

Summary

The hypothesis to be tested is that ticagrelor (Brilinta™) will reduce platelet activation and markers of inflammation in patients with pneumonia.

Conditions

  • Pneumonia
  • Community Acquired Pneumonia
  • Hospital Acquired Pneumonia
  • Acute Lung Injury

Interventions

DRUG

ticagrelor

DRUG

placebo

placebo

Sponsors & Collaborators

  • University of Kentucky

    lead OTHER

Principal Investigators

  • Susan S Smyth, MD PhD · University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2016-06-30
Completion
2016-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01883869 on ClinicalTrials.gov